Deborah M. Stephens, DO

home / authors / deborah-m-stephens-do

Articles

Optimizing the Treatment of CLL With Novel Therapies

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

William G. Wierda, MD, PhD;Jacqueline Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

William G. Wierda, MD, PhD;Jacqueline C. Barrientos, MD;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD;Deborah M. Stephens, DO

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Treating CLL With Anti-CD20 Antibody Regimens

William G. Wierda, MD, PhD;Deborah M. Stephens, DO;Catherine C. Coombs, MD;Nicole Lamanna, MD

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

William G. Wierda, MD, PhD;Anthony R. Mato, MD, MSCE;Catherine C. Coombs, MD;Deborah M. Stephens, DO

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors

William G. Wierda, MD, PhD;Jacqueline Barrientos, MD, MS;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO

February 7th 2022

Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.

Implications for Zanubrutinib as CLL Treatment

William G. Wierda, MD, PhD;Deborah M. Stephens, DO

January 31st 2022

An overview of safety and efficacy data for a third-generation Bruton tyrosine kinase inhibitor, zanubrutinib, as treatment for patients with chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Therapy for CLL

William G. Wierda, MD, PhD;Jacqueline Barrientos, MD, MS;Catherine C. Coombs, MD;Nicole Lamanna, MD;Anthony R. Mato, MD, MSCE;Deborah M. Stephens, DO

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Dr. Stephens on Early Intervention With Targeted Agents in CLL

Deborah M. Stephens, DO

November 15th 2021

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

Deborah M. Stephens, DO

November 12th 2021

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Stephens Discusses Optimizing Treatment Selection in CLL

Deborah M. Stephens, DO

November 9th 2021

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.